The trading price of Sanofi (NASDAQ:SNY) floating lower at last check on Wednesday, November 24, closing at $48.97, -1.88% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $49.61 and $50.04. The company’s P/E ratio in the trailing 12-month period was 17.85, while its 5Y monthly beta was 0.40. In examining the 52-week price action we see that the stock hit a 52-week high of $54.26 and a 52-week low of $45.17. Over the past month, the stock has gained 0.24% in value.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Sanofi, whose market valuation is $124.45 billion at the time of this writing. The dividend yield on the company stock is 3.87%, while its Forward Dividend ratio is 1.93. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $1.18 per share this quarter, however they have predicted annual earnings per share of $3.78 for 2021 and $4.39 for 2022. It means analysts are expecting annual earnings per share growth of 13.20% this year and 16.10% next year.
Analysts have forecast the company to bring in revenue of $12.07 billion for the current quarter, with the likely lows of $11.84 billion and highs of $12.34 billion. The average estimate suggests sales will likely up by 5.30% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $44.94 billion. The company’s revenue is forecast to grow by 9.40% over what it did in 2021.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Sanofi No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest SNY has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned SNY a recommendation rating is 26. Out of them, 5 rate it a Hold, while 16 recommend Buy, whereas 4 assign an Overweight rating. 0 analyst(s) have tagged Sanofi (SNY) as Underweight, while 1 advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 2.38, which symbolizes a positive outlook. A quick review shows that SNY’s price is currently -3.84% off the SMA20 and -1.03% off the SMA50. The RSI metric on the 14-day chart is currently showing 37.98, and weekly volatility stands at 0.89%. When measured over the past 30 days, the indicator reaches 1.01%. Sanofi (NASDAQ:SNY)’s beta value is currently sitting at 0.58, while the Average True Range indicator is currently displaying 0.68. With analysts defining $45.39-$71.41 as the low and high price targets, we arrive at a consensus price target of $61.70 for the trailing 12-month period. The current price is about 7.31% off the estimated low and -45.82% off the forecast high, based on this estimate. Investors will be thrilled if SNY’s share price rises to $61.88, which is the median consensus price. At that level, SNY’s share price would be -26.36% below current price.
To see how Sanofi stock has been performing today in comparison to its peers in the industry, here are the numbers: SNY stock’s performance was -1.88% at last check in today’s session, and 0.12% in the past year, while Eli Lilly and Company (LLY) has been trading -0.64% in recent session and positioned 82.70% higher than it was a year ago. Another comparable company Johnson & Johnson (JNJ) saw its stock trading -0.22% lower in today’s session but was up 11.69% in a year. Furthermore, Bristol-Myers Squibb Company (BMY) showed a decrease of -0.65% today while its price kept declining at -7.22% over the past year. Sanofi has a P/E ratio of 17.85, compared to Eli Lilly and Company’s 40.02 and Johnson & Johnson’s 24.02. Also during today’s trading, the S&P 500 Index has plunged -0.04%, while the Dow Jones Industrial also saw a negative session, down -0.22% today.
An evaluation of the daily trading volume of Sanofi (NASDAQ:SNY) indicates that the 3-month average is 1.86 million. However, this figure has increased over the past 10 days to an average of 1.37 million.
Currently, records show that 2.49 billion of the company’s shares remain outstanding. The insiders hold 16.40% of outstanding shares, whereas institutions hold 9.60%. The stats also highlight that short interest as of Aug 12, 2021, stood at 4.44 million shares, resulting in a short ratio of 2.71 at that time. From this, we can conclude that short interest is 0.18% of the company’s total outstanding shares. It is noteworthy that short shares in August were up slightly from the previous month’s figure, which was 3.93 million. However, since the stock’s price has seen 2.72% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.